Enjoy complimentary customisation on priority with our Enterprise License!
Japan - regenerative medicine market size is estimated to grow by USD 2,328.47 million at a CAGR of 15.89% between 2022 and 2027.
Stem cell therapy is a rapidly developing technology that can be applied to regenerative medicine. The use of stem cell technology in the treatment of diseases has increased its adoption rate. Furthermore, technological advances in stem cell-based therapies are changing the way researchers view regenerative medicine and are an important driver of these medical developments. Nanotechnology is also becoming increasingly important as a crucial tool in stem cell technology and regenerative medicine. Consequently, the growing adoption of stem cell technology will drive Japan regenerative medicine market size growth during the forecast period.
Technavio has segmented the market into Application, and Technology
This regenerative medicine market report also includes an in-depth analysis of drivers, trends, and challenges. Our report examines historic data from 2017 to 2021, besides analyzing the current market scenario.
To learn more about this report, Request Free Sample
The market share growth by the oncology segment will be significant during the forecast period. Regenerative therapy is used to increase the ability of a patient's immune system to fight cancer. Oncology regenerative medicine treats blood-related diseases such as non-Hodgkin's lymphoma, Hodgkin's lymphoma, multiple myeloma, and leukemia. For example, the monoclonal antibody rituximab (Rituxan) is used to treat lymphoma and leukemia, and lenalidomide (Revlimid) can be used for multiple myeloma.
Get a glance at the market contribution of various segments View a PDF Sample
The oncology segment was valued at USD 417.64 million in 2017. This segment is driven by factors such as the rising incidence of cancer in Japan. Therefore, there is a growing need for effective oncology regenerative medicine. Additionally, the focus on precision medicine and oncology research is further increasing the demand for regenerative medicine. Therefore, such factors are expected to drive the growth of regenerative medicine in the oncology applications segment, which in turn is expected to propel the growth of the market during the forecast period.
Cell therapy involves administering living cells to a single body to restore function to diseased or damaged body organs. The focus of cell- and tissue-based therapies is to repair and maintain the function of cells and tissues damaged by the development of various diseases such as cardiovascular diseases, cancer, musculoskeletal diseases, eye diseases, orthopedic diseases, neurological diseases, wounds and skin damage. However, regenerative therapy is only recommended for people who have no other treatment options. Approval of various new tissue-based regenerative medical devices and rising emphasis of companies on research and development to develop new cell- and tissue-based therapeutics will increase the cell- and tissue-based therapy segment during the forecast period. expected to be promoted.
Buy Now Full Report and Discover More
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:
Terumo Corp.: The company offers regenerative medicine such as Finia fill and finish system, Quantum cell expansion system and spectra Optia apheresis system.
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
There are multiple factors influencing market growth. Our researchers analyzed the data with 2022 as the base year, along with the key trends, and challenges.
Increasing number of clinical trials is the primary trend shaping the growth of the market. The increase in the number of clinical trials is mainly due to increased efforts and support from various international and national public and private associations. Many regenerative medicine products are in various stages of clinical trials, from discovery or preclinical to mid- and late-stage.
Furthermore, the significant increase in the number of clinical trials suggests that healthcare providers are increasingly focusing on regenerative medicine research and development. Increasing the number of products successfully completing clinical trials and receiving product approval will drive Japan - regenerative medicine market growth. There are few products in late-stage (Phase III) clinical trials that are anticipated to propel growth in Japan's regenerative medicine market
The scarcity of tissue donors is a challenge that affects the growth of the market. Market players that simulate regenerative products depend heavily on the availability of tissue from human donors. Several potential donor families may be reluctant to donate tissue to commercial tissue processors. Additionally, many suppliers are facing human tissue supply shortages due to limited control over availability, quality, and delivery times.
Therefore, any interruption in the supply of human tissue components will negatively impact the supplier's ability to produce regenerative products until a new source is found. Therefore, the lack of tissue donors is restricting the growth of the Japanese regenerative medicine market.
Buy Now Full Report and Discover More
The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Japan Regenerative Medicine Market Customer Landscape
The Japan regenerative medicine market report forecasts market growth by revenue and provides an analysis of the latest trends and growth opportunities from 2017 to 2027.
Japan Regenerative Medicine Market Scope |
|
Report Coverage |
Details |
Page number |
127 |
Base year |
2022 |
Historic period |
2017-2021 |
Forecast period |
2023-2027 |
Growth momentum & CAGR |
Accelerate at a CAGR of 15.89% |
Market growth 2023-2027 |
USD 2,328.47 million |
Market structure |
Fragmented |
YoY growth 2022-2023(%) |
14.75 |
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Key companies profiled |
Astellas Pharma Inc., Becton Dickinson and Co., CellSeed Inc., Cellusion Inc., Cyfuse Biomedical K.K., F. Hoffmann La Roche Ltd., FUJIFILM Corp., HEALIOS K.K., iHeart Japan Corp., Japan Tissue Engineering Co. Ltd., JCR Pharmaceticals Co. Ltd., MEDINET Co. Ltd., Metcela Inc., Nikon Corp., ROHTO Pharmaceutical Co. Ltd., Sumitomo Pharma Co. Ltd., Takara Bio Inc., Takeda Pharmaceutical Co. Ltd., Terumo Corp., and Yokogawa Electric Corp. |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and market condition analysis for the forecast period. |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
View Sample PDF at your Fingertips
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.